© 2000 American Heart Association, Inc.
Vascular Biology |
Interleukin-1 Receptor Antagonist Expression in Human Endothelial Cells and Atherosclerosis
From Cardiovascular Medicine, Division of Clinical Sciences, Northern General Hospital, and the Division of Molecular and Genetic Medicine (H.H.), University of Sheffield, Sheffield, UK.
Correspondence to Dr Sheila E. Francis, Cardiovascular Medicine, Division of Clinical Sciences, Northern General Hospital, Sheffield S5 7AU, UK. E-mail s.francis{at}sheffield.ac.uk
Abstract—The
proinflammatory cytokine interleukin (IL)-1 is expressed mainly
within the endothelium of atherosclerotic plaques and
may be linked with inflammatory mechanisms of atherogenesis. IL-1
action is complex and regulated in part by its naturally occurring
inhibitor, the IL-1 receptor antagonist
(IL-1ra). Therefore, we studied differential and specific isoform
expression of IL-1ra in the endothelium of diseased
coronary arteries and in endothelial cells
(ECs) stimulated under defined conditions. In view of an association
with IL-1ra gene (IL-1RN) polymorphism, the influence of
endothelial cell genotype at IL-1RN on IL-1ra
protein production was also examined. Secreted IL-1ra and
intracellular IL-1ra mRNAs were detected by semiquantitative reverse
transcription–polymerase chain reaction in human atherosclerotic and
dilated cardiomyopathic coronary arteries;
protein expression appeared increased in atherosclerotic compared with
dilated cardiomyopathic arteries, where IL-1ra appeared
to be confined to the endothelium. Only intracellular
IL-1ra type I mRNA was detected in human umbilical vein ECs (HUVECs)
and human coronary artery ECs (HCAECs) when they were
stimulated with bacterial lipopolysaccharide/phorbol
myristate acetate and transforming growth factor-ß. IL-1ß
and IL-1
were without effect. IL-1ra protein was detected in HUVECs
(intracellular IL-1ra), HCAECs (intracellular IL-1ra), and human
coronary artery smooth muscle cells (intracellular IL-1ra) by
immunoprecipitation and Western blot. IL-1ra was detected in
HUVEC cell lysates by ELISA and appeared to be influenced by the
genotype of the IL-1RN variable number tandem repeat, an
86-bp repeat polymorphism in intron 2 of the IL-1ra gene, with
lower levels of IL-1ra produced by IL-1RN allele 2–containing
cells (ratio of IL-1ra to total protein: for 1,1 homozygotes,
1.38±0.28x10-9 [n=15]; for 1,2
heterozygotes, 0.81±0.17x10-9 [n=8]; and
for 2,2 homozygotes, 0.63±0.19x10-9 [n=5];
P<0.05 compared with 1,1 homozygotes). This is the
first demonstration of IL-1ra in human diseased arteries, stimulated
HUVECs, and HCAECs and indicates the endothelial cell
as an important source. Endothelial IL-1ra
production may be controlled by the endothelial
IL-1RN genotype. These data further support the role of the
IL-1 system of cytokines in the pathogenesis of
atherosclerosis.
Key Words: interleukin-1 receptor antagonist • endothelium • inflammation • human coronary arteries
This article has been cited by other articles:
 |
|
 |
|
  P. Lu, L. Li, G. Liu, X. Zhang, and N. Mukaida Enhanced Experimental Corneal Neovascularization along with Aberrant Angiogenic Factor Expression in the Absence of IL-1 Receptor Antagonist Invest. Ophthalmol. Vis. Sci., October 1, 2009; 50(10): 4761 - 4768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Wingrove, S. E. Daniels, A. J. Sehnert, W. Tingley, M. R. Elashoff, S. Rosenberg, L. Buellesfeld, E. Grube, L. K. Newby, G. S. Ginsburg, et al. Correlation of Peripheral-Blood Gene Expression With the Extent of Coronary Artery Stenosis Circ Cardiovasc Genet, October 1, 2008; 1(1): 31 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Loppnow, K. Werdan, and M. Buerke Invited review: Vascular cells contribute to atherosclerosis by cytokine- and innate-immunity-related inflammatory mechanisms Innate Immunity, April 1, 2008; 14(2): 63 - 87. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Drosatos, D. Sanoudou, K. E. Kypreos, D. Kardassis, and V. I. Zannis A Dominant Negative Form of the Transcription Factor c-Jun Affects Genes That Have Opposing Effects on Lipid Homeostasis in Mice J. Biol. Chem., July 6, 2007; 282(27): 19556 - 19564. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. B. Worrall, T. G. Brott, R. D. Brown Jr, W. M. Brown, S. S. Rich, S. Arepalli, F. Wavrant-De Vrieze, J. Duckworth, A. B. Singleton, J. Hardy, et al. IL1RN VNTR Polymorphism in Ischemic Stroke: Analysis in 3 Populations Stroke, April 1, 2007; 38(4): 1189 - 1196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Gromadzka, I Sarzynska-Dlugosz, and A Czlonkowska IL1RN intron 2 polymorphism caused by variable number tandem repeats is associated with 1-year outcome in patients with ischaemic stroke J. Neurol. Neurosurg. Psychiatry, February 1, 2007; 78(2): 183 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tedgui and Z. Mallat Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways Physiol Rev, April 1, 2006; 86(2): 515 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Chamberlain, D. Evans, A. King, R. Dewberry, S. Dower, D. Crossman, and S. Francis Interleukin-1{beta} and Signaling of Interleukin-1 in Vascular Wall and Circulating Cells Modulates the Extent of Neointima Formation in Mice Am. J. Pathol., April 1, 2006; 168(4): 1396 - 1403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Hadjigeorgiou, K. Paterakis, E. Dardiotis, M. Dardioti, K. Aggelakis, A. Tasiou, G. Xiromerisiou, A. Komnos, E. Zintzaras, N. Scarmeas, et al. IL-1RN and IL-1B gene polymorphisms and cerebral hemorrhagic events after traumatic brain injury Neurology, October 11, 2005; 65(7): 1077 - 1082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kazi, C. Zhu, J. Roy, G. Paulsson-Berne, A. Hamsten, J. Swedenborg, U. Hedin, and P. Eriksson Difference in Matrix-Degrading Protease Expression and Activity Between Thrombus-Free and Thrombus-Covered Wall of Abdominal Aortic Aneurysm Arterioscler Thromb Vasc Biol, July 1, 2005; 25(7): 1341 - 1346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Shepherd and M. J.H. Nicklin Elastic-Vessel Arteritis in Interleukin-1 Receptor Antagonist-Deficient Mice Involves Effector Th1 Cells and Requires Interleukin-1 Receptor Circulation, June 14, 2005; 111(23): 3135 - 3140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Merhi-Soussi, B. R. Kwak, D. Magne, C. Chadjichristos, M. Berti, G. Pelli, R. W. James, F. Mach, and C. Gabay Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice Cardiovasc Res, June 1, 2005; 66(3): 583 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. L. Wilson, S. E. Francis, S. K. Dower, and D. C. Crossman Secretion of Intracellular IL-1 Receptor Antagonist (Type 1) Is Dependent on P2X7 Receptor Activation J. Immunol., July 15, 2004; 173(2): 1202 - 1208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Isoda, S. Sawada, N. Ishigami, T. Matsuki, K. Miyazaki, M. Kusuhara, Y. Iwakura, and F. Ohsuzu Lack of Interleukin-1 Receptor Antagonist Modulates Plaque Composition in Apolipoprotein E-Deficient Mice Arterioscler Thromb Vasc Biol, June 1, 2004; 24(6): 1068 - 1073. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G F Ferraccioli and E Gremese Autoantibodies and thrombophilia in RA: TNF{alpha} and TNF{alpha} blockers Ann Rheum Dis, June 1, 2004; 63(6): 613 - 615. [Full Text]
|
|
|
|
 |
|
 R. M. Dewberry, D. C. Crossman, and S. E. Francis Interleukin-1 Receptor Antagonist (IL-1RN) Genotype Modulates the Replicative Capacity of Human Endothelial Cells Circ. Res., June 27, 2003; 92(12): 1285 - 1287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. B. Worrall, S. Azhar, P. A. Nyquist, R. H. Ackerman, T. L. Hamm, and T. J. DeGraba Interleukin-1 Receptor Antagonist Gene Polymorphisms in Carotid Atherosclerosis Stroke, March 1, 2003; 34(3): 790 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Kharbanda, B. Walton, M. Allen, N. Klein, A. D. Hingorani, R. J. MacAllister, and P. Vallance Prevention of Inflammation-Induced Endothelial Dysfunction: A Novel Vasculo-Protective Action of Aspirin Circulation, June 4, 2002; 105(22): 2600 - 2604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F.-J. Tsai, Y.-Y. Hsieh, C.-C. Chang, C.-C. Lin, and C.-H. Tsai Polymorphisms for Interleukin 1{beta} Exon 5 and Interleukin 1 Receptor Antagonist in Taiwanese Children With Febrile Convulsions Arch Pediatr Adolesc Med, June 1, 2002; 156(6): 545 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Devlin, G. Kuriakose, E. Hirsch, and I. Tabas Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size PNAS, April 30, 2002; 99(9): 6280 - 6285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. HUTYROVA, P. PANTELIDIS, J. DRABEK, M. ZURKOVA, V. KOLEK, K. LENHART, K. I. WELSH, R. M. DU BOIS, and M. PETREK Interleukin-1 Gene Cluster Polymorphisms in Sarcoidosis and Idiopathic Pulmonary Fibrosis Am. J. Respir. Crit. Care Med., January 15, 2002; 165(2): 148 - 151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S E Francis, N J Camp, A J Burton, R M Dewberry, J Gunn, A Stephens-Lloyd, D C Cumberland, A Gershlick, and D C Crossman Interleukin 1 receptor antagonist gene polymorphism and restenosis after coronary angioplasty Heart, September 1, 2001; 86(3): 336 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tedgui and Z. Mallat Anti-Inflammatory Mechanisms in the Vascular Wall Circ. Res., May 11, 2001; 88(9): 877 - 887. [Abstract] [Full Text] [PDF]
|
|